Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 Single Agent for Refractory Solid Tumors (ME-344-001)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01544322
Recruitment Status : Completed
First Posted : March 5, 2012
Last Update Posted : June 18, 2015
SCRI Development Innovations, LLC
Information provided by (Responsible Party):
MEI Pharma, Inc.

Brief Summary:
The purpose of this study is to determine the tolerability of ME-344, find the maximum tolerated dose, and the safety profile in patients with refractory solid tumors.

Condition or disease Intervention/treatment Phase
Solid Tumors Drug: ME-344 Phase 1

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1 Open Label Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 as a Single Agent in Patients With Refractory Solid Tumors
Study Start Date : May 2012
Actual Primary Completion Date : August 2014
Actual Study Completion Date : August 2014

Intervention Details:
  • Drug: ME-344

    experimental drug, dose escalation with 5 planned dose cohorts of 1.2 mg/kg, 2.5 mg/kg, 5 mg/kg, 10 mg/kg, 20 mg/kg; Cycle 1 is 3 weekly IV infusions on Days 1, 8, and 15. After safety assessment, if there is clinical benefit, weekly dosing may continue until withdrawal.

    Once the highest tolerated dose has been determined, patients will be enrolled to receive IV infusions 2 days each week. Cycle 1 at the highest dose level is 3 weekly IV infusions on days 1, 2, 8, 9, 15 and 16. After safety assessment, if there is clinical benefit, weekly dosing may continue until withdrawal.

    Other Names:
    • open label
    • single agent

Primary Outcome Measures :
  1. Dose limiting toxicity [ Time Frame: One Cycle of 28 days ]
    Patients will be administered ME-344 IV infusions weekly for 3 weeks during the first 28 days cycle for dose limiting toxicity. Patients will be assessed by physical exam, vital signs, hematology and clinical chemistry, urinalysis, ECG, echocardiogram and pharmacokinetic sampling.

Secondary Outcome Measures :
  1. Response Rate [ Time Frame: baseline and a minimum of every 12 weeks ]
    Radiologic assessments will be performed at baseline and a minimum of every 12 weeks. Patients may continue weekly dosing if there is clinical beneficial determined by the Investigator.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Provision of informed consent
  • Male or female ≥ 18 years of age
  • Histologic or cytologic confirmed locally advanced or metastatic cancer that has no standard therapeutic alternatives.
  • ECOG Performance status 0-1 (Appendix A)
  • A minimum life expectancy of 12 weeks
  • Adequate bone marrow, hepatic and renal function as evidenced by:

    • Absolute neutrophil count (ANC) > 1.5 x 109/L
    • Platelet count > 100 x 109/L
    • Hemoglobin > 9.0 g/dL
    • Serum bilirubin < 1.5 x ULN
    • AST/ALT (SGOT/SGPT) < 2.5 x ULN for the reference laboratory or < 5 x ULN in the presence of liver metastases
    • Serum creatinine < 1.5 x ULN
  • Adequate cardiac function as evidenced by:

    • CK-MB within normal levels at baseline
    • Troponin T within normal levels at baseline
    • The average QTc from triplicate screening ECGs (every 5 minutes over a total of 15 minutes) must be < 470 msec to be eligible for the study. (If a patient has an average QTc interval >470 msec at screening, the screening ECG may be repeated twice (at least 24 hours apart).
    • LV Ejection Fraction > lower limit of institutional normal level
  • All potentially fertile patients will agree to use an effective form of contraception during the study and for 30 days following the last dose of ME-344 (an effective form of contraception is defined as an oral contraceptive or a double barrier method).
  • At least 4 weeks must have elapsed prior to Day 1 Cycle 1 since prior chemotherapy (6 weeks for nitrosourea or mitomycin C), investigational drug or biologic therapy and any toxicity associated with these treatments has recovered to ≤ NCI-CTCAE Grade 1.
  • At least 21 days must have elapsed prior to Day 1 Cycle 1, radiotherapy, immunotherapy or following major surgery and any surgical incision should be completely healed. At least 14 days must have elapsed prior to Day 1 Cycle 1 for "limited palliative radiotherapy", defined as a course of therapy encompassing <25% total bone marrow volume and not exceeding 30 Gy.

Exclusion Criteria:

  • Patients who are pregnant or breastfeeding
  • Tumor involvement of the Central Nervous System (CNS):

    • Patients with treated and stable CNS metastases may be eligible to participate after discussion and approval from the Medical Monitor
  • Uncontrolled infection or systemic disease.
  • Clinically significant cardiac disease not well controlled with medication (e.g., congestive heart failure, symptomatic coronary artery disease e.g. angina, and cardiac arrhythmias) or myocardial infarction within the last 12 months.
  • Any major surgery, radiotherapy, or immunotherapy within the last 21 days. Limited palliative radiation, defined as encompassing <25% of total bone marrow volume and not exceeding a total dose of 30 Gy, within the last 14 days.
  • Chemotherapy regimens with delayed toxicity within the last 4 weeks (or within 6 weeks for prior nitrosourea or mitomycin C). Chemotherapy regimens given continuously or on a weekly basis with limited potential or delayed toxicity within the last 2 weeks.
  • No concurrent systemic chemotherapy or biologic therapy is allowed.
  • Known hypersensitivity to any components of ME-344 study drug product.
  • Known human immunodeficiency virus (HIV) or Hepatitis B or C (active, previously treated or both).
  • History of solid organ transplantation.
  • Psychiatric disorder or social or geographic situation that would preclude study participation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01544322

United States, Florida
Florida Cancer Specialists
Sarasota, Florida, United States, 34232
United States, Oklahoma
University of Oklahoma
Oklahoma City, Oklahoma, United States, 73104
United States, Tennessee
Tennessee Oncology, PLLC
Nashville, Tennessee, United States, 73104
Sponsors and Collaborators
MEI Pharma, Inc.
SCRI Development Innovations, LLC
Study Chair: Robert D Mass, MD MEI Pharma, Inc.

Additional Information:
Responsible Party: MEI Pharma, Inc. Identifier: NCT01544322     History of Changes
Other Study ID Numbers: ME-344-001
First Posted: March 5, 2012    Key Record Dates
Last Update Posted: June 18, 2015
Last Verified: April 2014

Keywords provided by MEI Pharma, Inc.:
solid tumors